Pliant Therapeutics, Inc. (PLRX) — SEC Filings
Pliant Therapeutics, Inc. (PLRX) — 42 SEC filings. Latest: EFFECT (Apr 7, 2026). Includes 16 8-K, 8 SC 13G/A, 8 SC 13G.
View Pliant Therapeutics, Inc. on SEC EDGAR
Overview
Pliant Therapeutics, Inc. (PLRX) is a publicly traded company tracked on ReadTheFiling. The most recent enriched filing is a 8-K filed on Dec 16, 2025: Pliant Therapeutics, Inc. announced on December 10, 2025, changes in its board of directors and executive compensation arrangements. Specifically, the company elected two new directors, Dr. Jonathan Leff and Ms. Sarah Emens, to its Board of Directors. Additionally, the company entered into new emplo
Sentiment Summary
Across 42 filings, the sentiment breakdown is: 2 bullish, 1 bearish, 38 neutral, 1 mixed. The dominant filing sentiment for Pliant Therapeutics, Inc. is neutral.
Filing Type Overview
Pliant Therapeutics, Inc. (PLRX) has filed 1 EFFECT, 16 8-K, 6 10-Q, 2 DEF 14A, 1 10-K, 8 SC 13G/A, 8 SC 13G with the SEC between Jan 2024 to Apr 2026.
Filings by Year
Recent SEC Filings (42)
Risk Profile
Risk Assessment: Of PLRX's 26 recent filings, 2 were flagged as high-risk, 12 as medium-risk, and 12 as low-risk. The overall risk profile suggests relatively low risk with generally favorable filings.
Financial Highlights
| Metric | Value |
|---|---|
| Revenue | N/A |
| Net Income | -$26.301M |
| EPS | N/A |
| Debt-to-Equity | 0.38 |
| Cash Position | $93.732M |
| Operating Margin | N/A |
| Total Assets | $276.600M |
| Total Debt | $30.439M |
Key Executives
- Dr. Jonathan Leff
- Ms. Sarah Emens
- Dr. Louis Pascarella
- Mr. David L. Lee
- Dr. David J. Weitz
- Dr. David M. Lee
- Dr. David J. E. Mann
- Abigail P. Johnson
Industry Context
Pliant Therapeutics operates in the highly competitive and capital-intensive biopharmaceutical industry, focusing on developing treatments for fibrotic and related diseases. The sector is characterized by long development cycles, high R&D costs, and significant regulatory oversight. Success hinges on clinical trial outcomes and the ability to navigate complex approval pathways.
Top Tags
10-Q (4) · executive-compensation (3) · corporate-governance (3) · disclosure (3) · biotech (3) · institutional-ownership (3) · management-change (2) · board-of-directors (2) · personnel (2) · Biotechnology (2)
Key Numbers
| Metric | Value | Context |
|---|---|---|
| Net Loss (Q3 2025) | $26.301M | Reduced from $57.763M in Q3 2024 |
| Net Loss (YTD Q3 2025) | $125.767M | Reduced from $160.572M in YTD Q3 2024 |
| Research and Development Expenses (Q3 2025) | $17.938M | Significant decrease from $47.754M in Q3 2024 |
| Research and Development Expenses (YTD Q3 2025) | $93.572M | Significant decrease from $130.517M in YTD Q3 2024 |
| Cash and Cash Equivalents (Sept 30, 2025) | $93.732M | Increased from $71.188M at Dec 31, 2024 |
| Short-term Investments (Sept 30, 2025) | $148.065M | Decreased from $284.536M at Dec 31, 2024 |
| Total Assets (Sept 30, 2025) | $276.600M | Decreased from $396.949M at Dec 31, 2024 |
| Total Liabilities (Sept 30, 2025) | $76.294M | Decreased from $92.868M at Dec 31, 2024 |
| Net Loss (Q2 2025) | $49.7M | Increased from $38.2M in Q2 2024, indicating higher operating expenses. |
| Net Loss (YTD June 2025) | $97.8M | Widened from $74.5M in YTD June 2024, reflecting increased investment in R&D. |
| Revenue (Q2 2025) | $10.5M | Decreased by 13.2% from $12.1M in Q2 2024, primarily due to collaboration revenue fluctuations. |
| R&D Expenses (Q2 2025) | $48.3M | Increased from $39.5M in Q2 2024, driven by ongoing clinical trials for bexotegrast. |
| Cash & Equivalents (June 30, 2025) | $450.2M | Provides significant liquidity to fund operations and clinical development for the foreseeable future. |
| Reporting Period End Date | 2025-03-31 | Quarterly financial reporting |
| Reporting Period Start Date | 2025-01-01 | Quarterly financial reporting |
Forward-Looking Statements
- {"claim":"FMR LLC will maintain a significant, albeit potentially fluctuating, stake in Pliant Therapeutics Inc. for the foreseeable future.","entity":"FMR LLC","targetDate":"2025-02-09","confidence":"medium"}
- {"claim":"Pliant Therapeutics' stock price may see a short-term positive reaction due to increased institutional interest.","entity":"PLIANT THERAPEUTICS, INC.","targetDate":"Q1 2024","confidence":"medium"}
- {"claim":"Laurion Capital Management LP will maintain or increase its stake in Pliant Therapeutics over the next year.","entity":"Laurion Capital Management LP","targetDate":"Q4 2024","confidence":"low"}
Related Companies
Frequently Asked Questions
What are the latest SEC filings for Pliant Therapeutics, Inc. (PLRX)?
Pliant Therapeutics, Inc. has 42 recent SEC filings from Jan 2024 to Apr 2026, including 16 8-K, 8 SC 13G/A, 8 SC 13G. Each filing includes an AI-generated plain-English summary.
What is the overall sentiment of PLRX filings?
Across 42 filings, the sentiment breakdown is: 2 bullish, 1 bearish, 38 neutral, 1 mixed. The dominant sentiment is neutral.
Where can I find Pliant Therapeutics, Inc. SEC filings explained simply?
ReadTheFiling provides AI-powered plain-English summaries of all Pliant Therapeutics, Inc. (PLRX) SEC filings, including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, and insider trades.
What are the key financial highlights for Pliant Therapeutics, Inc.?
Key financial highlights from Pliant Therapeutics, Inc.'s most recent 10-Q include metrics such as revenue, net income, EPS, and debt ratios. Visit the filing detail page for the full breakdown.
What is the investment thesis for PLRX?
The investment thesis for PLRX includes bull, base, and bear case scenarios derived from AI analysis of recent SEC filings.
Who are the key executives at Pliant Therapeutics, Inc.?
Key executives identified across Pliant Therapeutics, Inc.'s filings include Dr. Jonathan Leff, Ms. Sarah Emens, Dr. Louis Pascarella, Mr. David L. Lee, Dr. David J. Weitz and 3 others.
What are the main risk factors for Pliant Therapeutics, Inc. stock?
Of PLRX's 26 assessed filings, 2 were flagged high-risk, 12 medium-risk, and 12 low-risk.
What are recent predictions and forward guidance from Pliant Therapeutics, Inc.?
Recent forward-looking statements from Pliant Therapeutics, Inc. include guidance on {"claim":"FMR LLC will maintain a significant, albeit potentially fluctuating, stake in Pliant Therapeutics Inc. for the and 2 other predictions.